Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

BACKGROUND: We assessed the maximum tolerated regimen (MTR) and dose-limiting toxicities of pazopanib and lapatinib in combination with weekly paclitaxel, and the effect of pazopanib and lapatinib on paclitaxel pharmacokinetics. METHODS: Patients received intravenous paclitaxel on days 1, 8, and 15...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Tan, A R, Dowlati, A, Stein, M N, Jones, S F, Infante, J R, Bendell, J, Kane, M P, Levinson, K T, Suttle, A B, Burris III, H A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2014
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4037836/
https://ncbi.nlm.nih.gov/pubmed/24800949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.233
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller